Charles R Dunlop

Publication Activity (10 Years)

Years Active: 2018-2020
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Dna Damage Response

Top Venues

Science signaling

Cancer research

British journal of cancer

Molecular cancer therapeutics

University of Cambridge (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Cambridge Oct 01 2016

United Kingdom

PHD :: CRUK Cambridge Institute

Publications

Charles N Birts, Arindam Banerjee, Matthew Darley, Charles R Dunlop, Sarah Nelson, Sharandip K Nijjar, Rachel Parker, Jonathan J West, Ali Tavassoli, Matthew J J Rose-Zerilli, Jeremy P Blaydes
p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators. Science signaling 13 (630) (2020)
Charles R Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T Durant, Elaine B Cadogan, Alan Lau, Frances M Richards, Duncan Ian Jodrell
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. British journal of cancer 123 (9) (2020)
Yann Wallez, Charles R Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W T Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M Richards, Duncan I Jodrell
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Molecular cancer therapeutics 17 (8) (2018)
Siang-Boon Koh, Yann Wallez, Charles R Dunlop, Sandra Bernaldo de Quirós Fernández, Tashinga E Bapiro, Frances M Richards, Duncan I Jodrell
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. Cancer research 78 (11) (2018)